Pharming Group (NASDAQ:PHAR - Free Report) had its price objective hoisted by Oppenheimer from $30.00 to $39.00 in a research report released on Friday,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.
PHAR has been the subject of a number of other research reports. HC Wainwright restated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research note on Friday. Jefferies Financial Group began coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a "buy" rating and a $14.00 target price for the company.
Read Our Latest Stock Analysis on PHAR
Pharming Group Price Performance
Shares of NASDAQ:PHAR remained flat at $8.80 during mid-day trading on Friday. The company had a trading volume of 6,598 shares, compared to its average volume of 6,206. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $598.67 million, a P/E ratio of -33.85 and a beta of -0.10. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $11.32. The business's 50 day moving average price is $8.95 and its 200 day moving average price is $8.60.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.02). The company had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. Analysts anticipate that Pharming Group will post -0.2 EPS for the current fiscal year.
Institutional Trading of Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its holdings in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 47,997 shares of the company's stock after acquiring an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 as of its most recent filing with the SEC. 0.03% of the stock is currently owned by institutional investors.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
